BostonGene logo
Biologically grounded AI for drug development and precision clinical decision-making
Transform multimodal biology into simulation-driven therapeutic strategy, patient selection, and predictive clinical intelligence.
BostonGene's platform combines deep biological insights with advanced AI and this collaboration will empower us to predict which patients will benefit from treatment helping us design safer, more effective therapies from the start.
Jorge Reis-Filho, MD, PhD, Chief of AI for Science
Innovation, Enterprise AI Unit, AstraZeneca
BostonGene Collaboration Image with AstraZeneca
This partnership allows us to leverage our AI-driven technologies for a more comprehensive understanding of cancer biology.
Nathan Fowler, MD,
Chief Medical Officer at BostonGene
BostonGene Collaboration Image with Johnson & Johnson
The challenge of immune resistance in cancer treatment requires clinically precise solutions that address not only immune suppression, but also immune exclusion.
Robert Tighe, SVP Preclinical and Translational
Sciences at Ottimo Pharma
BostonGene Collaboration Image with Ottimo Pharma
Our work with Daiichi Sankyo is focused on accelerating learning cycles, lowering the cost of uncertainty, and differentiating this medicine earlier by identifying where it will most likely benefit patients with cancer.
Nathan Fowler, MD,
Chief Medical Officer at BostonGene
BostonGene Collaboration Image with Daiichi Sankyo
Patient-specific cancer-immune biological modeling
Integrating tumor and immune biology at the patient level to guide therapy development and increase probability of success.
Patient-specific Biological Modeling

From prediction
to disease-level simulation

From prediction to disease-level simulation

Building organism-level models that simulate intervention response and drive high-value oncology decisions.

Predictive AI

Analyzes only historical data

Identifies simple biological patterns

Predicts clinical outcomes

Asks "What is likely to happen?"

Supports retrospective analysis

Simulational AI
by BostonGene

Simulates state, dynamics, and intervention

Models disease-level biology

Represents future therapeutic responses

Asks "What happens if we intervene?"

Supports strategic decision-making

Globally recognized AI-powered platform

Cancer Cell award logo
F&S award logo
Fierce award logo
Stevie Awards logo
Clinical Trials Arena award logo
Pharma Tech award logo
GRASP award logo

Transforming patient outcomes through clinical precision

We perform advanced clinical testing in our high-complexity in-house laboratory to generate clinical-grade tumor and immune data that power disease-level modeling and critical oncology decisions.

BostonGene Tumor Portrait® test

The Tumor Portrait test identifies key biomarkers for response to various therapies in patients with advanced solid tumors.

Immune system profiling

Snapshot of the patient’s immune health by identification of hundreds of different cell types from a single tube of blood.

Immunohistochemistry (IHC) test

Testing for clinically actionable biomarkers such as PD-L1 & MMR

Unknown Primary test

Identifies the tumor’s origin using DNA and RNA sequencing.

BostonGene in-house laboratory

Multimodal clinical lab capabilities for tumor and immune profiling.

Visit laboratory solutions

CERTIFICATION & ACCREDITATION*

New York State Department of Health logo
College of American Pathologists (CAP) logo
Clinical Laboratory Improvement Amendments (CLIA) logo
ISO certification logo

*We actively maintain and regularly review all certifications listed on this page to ensure accuracy and currency. As certification status may occasionally change due to renewal cycles or issuing-body updates, please contact us directly to confirm the most current credentials for formal business or compliance purposes.

Select academic partners

Mass General Brigham logo
MD Anderson Cancer Center logo
Dana-Farber Cancer Institute logo
Mayo Clinic logo

*We actively maintain and regularly review all certifications listed on this page to ensure accuracy and currency. As certification status may occasionally change due to renewal cycles or issuing-body updates, please contact us directly to confirm the most current credentials for formal business or compliance purposes.

Driving real world impact

Trusted by leading pharma and biotech companies. We leverage our deep clinical foundation to build strategic, long-term partnerships across the drug development lifecycle.

Read our case studies to see how we turn complex multiomic data into successful clinical outcomes.

Contact Us
Prioritize indications and subtypes based on molecular signals
AI and digital twins predict therapy response and unlock high-value indications
Learn more
Stratify patients and optimize trials with AI-driven classifiers
AI classifier enables leaner trials with precise patient targeting
Learn more
Identify BTK-inh responder cohort to support label expansion
AI reveals responder cohorts to accelerate label expansion opportunities
Learn more

Partner with us

Turn complex biology into a strategic advantage.

Contact us